CASP3 and ganglioneuroma: The apoptotic marker cleaved caspase-3 was significantly increased in groups treated with anti-EGFR (141.11±11.10%), anti-EGFR-GN (259.08±17.23%), and anti-EGFR-GN+NIR-PTT (422.33±61.36%) relative to control.